Granules India subsidiary receives USFDA EIR for Chantilly facility
Granules Pharmaceuticals, a subsidiary of Granules India Limited, received a USFDA Establishment Inspection Report for its Chantilly facility. The inspection concluded with a Voluntary Action Indicated classification and four observations, indicating no mandatory regulatory action is required.
*this image is generated using AI for illustrative purposes only.
Granules Pharmaceuticals, a subsidiary of Granules India Limited , has received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Chantilly facility. The inspection concluded with a Voluntary Action Indicated (VAI) classification, recording four observations at the site. The company communicated this development to the National Stock Exchange of India Limited and BSE Limited on June 03, 2026.
USFDA Inspection Outcome
The USFDA issued the EIR following a completed inspection of the Chantilly facility. The inspection recorded four observations, and the facility has been classified under the Voluntary Action Indicated (VAI) category. A VAI classification signifies that while observations were noted during the inspection, the USFDA does not consider the findings to warrant mandatory regulatory action against the facility.
Key details of the regulatory development are summarised below:
| Parameter | Details |
|---|---|
| Entity | Granules Pharmaceuticals (Subsidiary of Granules India Limited) |
| Regulatory Body | USFDA |
| Document Received | Establishment Inspection Report (EIR) |
| Facility | Chantilly Facility |
| Classification | Voluntary Action Indicated (VAI) |
| Number of Observations | Four |
Significance of the VAI Classification
The VAI classification is one of three possible outcomes following a USFDA facility inspection, the others being No Action Indicated (NAI) and Official Action Indicated (OAI). A VAI status indicates that inspectional observations were made, but these do not rise to the level requiring official regulatory action. This outcome reflects the facility's overall compliance standing with USFDA standards following the inspection with four observations.
Historical Stock Returns for Granules
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.19% | +0.93% | +12.29% | +39.45% | +49.78% | +140.92% |
How will the VAI classification impact the timeline for new product approvals from the Chantilly facility?
What specific corrective actions does Granules Pharmaceuticals plan to implement to address the four observations?
Could this regulatory outcome affect the company's partnerships or supply chain agreements with US-based clients?
19
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
